Synlogic (SYBX)

• Market cap: $20.7M
• 1 day: 2.91%
• 5 days: -3.28%
• 1 month: 4.12%
• 3 months: 5.99%
• 6 months: 52.59%
• Year to date: 24.65%
• 1 year: 23.78%
• 5 years: -93.85%
• 10 years: -99.72%
• Sector: Healthcare
• Industry: Biotechnology

About: Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Employees: 1